{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:32:50Z","timestamp":1784601170121,"version":"3.55.0"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple primary tumors, especially quadruple primary tumors, are extremely rare clinically, and there is no standard protocol for clinical management. We described a case in which a bone tumor, a malignant bladder tumor, a malignant melanoma, and an intrahepatic cholangiocarcinoma were all original malignancies. The patient is a 79-year-old woman who underwent surgery for a left middle finger bone tumor 45 years ago, as well as surgery for bladder malignancy and postoperative adjuvant chemotherapy 15 years ago, and the precise pathological results and treatment are unclear. One year ago, she underwent amputation of the toe due to a black mass of the right toe and was diagnosed pathologically as a freckled malignant melanoma of the extremity. Prior to postoperative adjuvant systemic medication, PET\/CT revealed malignancy in the lateral segment of the left lobe of the liver, and multiple lymphadenopathies in the left parotid gland, hilar hepatic, and retroperitoneal region. Intrahepatic cholangiocarcinoma was found in the liver puncture biopsy\u2019s pathology report. The serum sample\u2019s next-generation sequencing (NGS) revealed a missense mutation, designated P.G12V, in exon 2 of the KRAS gene. Based on patients with malignant melanoma and intrahepatic cholangiocarcinoma, she received 6 cycles of GP (gemcitabine\/cisplatin) combined with Camrelizumab systemic therapy, and followed by 3 cycles of Camrelizumab maintenance therapy, the efficacy was evaluated as stable disease (SD) during treatment. When the 4th cycle of Camrelizumab was suggested for maintenance therapy, the efficacy evaluation revealed that the tumor had greatly advanced. The patient refused to continue anti-tumor therapy and passed away from septic shock and multiple organ failure 3 months later. The patient had satisfactory efficacy and lived for a year after being diagnosed with two primary cancers. Despite the rarity of quadruple primary tumors and the lack of a conventional clinical management strategy, we postulate that germline mutations in the KRAS gene may be closely associated with the formation and development of multiple primary tumors. NGS testing is necessary for clinical management, and systemic treatment based on concurrent multiple main tumors is the key to improving prognosis.<\/jats:p>","DOI":"10.3389\/fonc.2022.1090634","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T17:28:42Z","timestamp":1672853322000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Multiple primary malignant neoplasm: Case report and comprehensive literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Xue-Yan","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"B1","article-title":"Multiple primary malignant neoplasms","volume":"18","author":"Hunt","year":"1933","journal-title":"J Lab Clin Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10779","article-title":"Multiple primary malignant neoplasms: A case report and literature review","volume":"18","author":"Zhang","year":"2019","journal-title":"Oncol letters"},{"key":"B3","article-title":"Multiple primary malignant tumors. a survey of the literature and a statistical study","volume":"16","author":"Warren","year":"1932","journal-title":"Am J Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1186\/s12891-020-03426-8","article-title":"Multiple primary tumors: a case report and review of the literature","volume":"21","author":"Zhao","year":"2020","journal-title":"BMC musculoskeletal Disord"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/150960","article-title":"Clinical relevance of KRAS in human cancers","volume":"2010","author":"Janc\u00edk","year":"2010","journal-title":"J biomed Biotechnol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015388","article-title":"Melanoma: clinical features and genomic insights","volume":"4","author":"Hawryluk","year":"2014","journal-title":"Cold Spring Harbor Perspect Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2000.00877.x","article-title":"Mutation and allelic loss of the PTEN\/MMAC1 gene in primary and metastatic melanoma biopsies","volume":"114","author":"Birck","year":"2000","journal-title":"J Invest Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-13-0142","article-title":"Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma","volume":"19","author":"Kwong","year":"2013","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11081341","article-title":"Unraveling the wide spectrum of melanoma biomarkers","volume":"11","author":"Revythis","year":"2021","journal-title":"Diagnostics"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102070","article-title":"KRAS: From undruggable to a druggable cancer target","volume":"89","author":"Uprety","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-020-09915-5","article-title":"Molecular epidemiology and diagnostics of KRAS mutations in human cancer","volume":"39","author":"Timar","year":"2020","journal-title":"Cancer metastasis Rev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19031106","article-title":"Non-epithelial ovarian cancers: How much do we really know","volume":"19","author":"Cheung","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.4787","article-title":"Genetics of biliary tract cancers and emerging targeted therapies","volume":"28","author":"Hezel","year":"2010","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ccell.2021.12.006","article-title":"Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma","volume":"40","author":"Dong","year":"2022","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13321","article-title":"Mutational profiling of acral melanomas in Korean populations","volume":"26","author":"Shim","year":"2017","journal-title":"Exp Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1038\/onc.2017.391","article-title":"Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition","volume":"37","author":"Dietrich","year":"2018","journal-title":"Oncogene."},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2012.04309.x","article-title":"KRAS mutation is present in a small subset of primary urinary bladder adenocarcinomas","volume":"61","author":"Alexander","year":"2012","journal-title":"Histopathology."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-013-2512-8","article-title":"The prevalence and prognostic significance of KRAS mutation in bladder cancer, chronic myeloid leukemia and colorectal cancer","volume":"40","author":"Ouerhani","year":"2013","journal-title":"Mol Biol Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e13821","DOI":"10.1371\/journal.pone.0013821","article-title":"FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy","volume":"5","author":"Kompier","year":"2010","journal-title":"PloS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/mph.0000000000002112","article-title":"Malignant giant cell tumor of bone with a KRAS G12V mutation","volume":"44","author":"Donigian","year":"2022","journal-title":"J Pediatr hematology\/oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.2384","article-title":"Multiple primary malignant neoplasms in an elderly patient","volume":"10","author":"Parekh","year":"2018","journal-title":"Cureus."},{"key":"B22","first-page":"1992","article-title":"SEER cancer statistics review, 1975\u20132013","author":"Howlader","year":"2016","journal-title":"Natl Cancer Instit"},{"key":"B23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/pcmr.12885","article-title":"Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease","volume":"34","author":"Basurto-Lozada","year":"2021","journal-title":"Pigment Cell melanoma Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1186\/s12885-019-6248-2","article-title":"Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan clinical oncology group study (JCOG1602, J-NAIL study protocol)","volume":"19","author":"Tanaka","year":"2019","journal-title":"BMC cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103208","article-title":"Melanoma of unknown primary: New perspectives for an old story","volume":"158","author":"Boussios","year":"2021","journal-title":"Crit Rev oncology\/hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":":e20201979","DOI":"10.1084\/jem.20201979","article-title":"Immune checkpoint inhibitors","volume":"218","author":"Kroemer","year":"2021","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30671-0","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): Interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: First global approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs."},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.9554","article-title":"Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma\u2013a single-arm, multicenter, phase II study","volume":"39","author":"Lian","year":"2021","journal-title":"Wolters Kluwer Health"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"New Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00065-6","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG\/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial","volume":"22","author":"Eggermont","year":"2021","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02110","article-title":"Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG\/KEYNOTE-054 trial","volume":"38","author":"Eggermont","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"New Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30417-7","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial","volume":"395","author":"Zimmer","year":"2020","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.36_suppl.356154","article-title":"DREAMseq (Doublet, randomized evaluation in advanced melanoma sequencing): A phase III trial\u2013ECOG-ACRIN EA6134","volume":"39","author":"Atkins","year":"2021","journal-title":"Am Soc Clin Oncol"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.2275","article-title":"LBA45 first report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo immuno and targeted therapy study)","volume":"31","author":"Ascierto","year":"2020","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.9508","article-title":"A phase II clinical trial of camrelizumab (CAM, an IgG4 antibody against PD-1) combined with apatinib (APA, a VEGFR-2 tyrosine kinase inhibitor) and temozolomide (TMZ) as the first-line treatment for patients (pts) with advanced acral melanoma (AM)","volume":"40","author":"Si","year":"2022","journal-title":"Am Soc Clin Oncol"},{"key":"B39","doi-asserted-by":"crossref","first-page":"15330338211039952","DOI":"10.1177\/15330338211039952","article-title":"Application of immune checkpoint inhibitors in the treatment of cholangiocarcinoma","volume":"20","author":"Zeng","year":"2021","journal-title":"Technol Cancer Res Treat"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.64","article-title":"Quality of life, long-term survivors and long-term outcome from the ABC-02 study","volume":"114","author":"Bridgewater","year":"2016","journal-title":"Br J cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.4074","article-title":"A phase II study of anti\u2013PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer","volume":"37","author":"Qin","year":"2019","journal-title":"Am Soc Clin Oncol"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2020.08.056","article-title":"78TiP KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","volume":"31","author":"Valle","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1090634\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T17:28:50Z","timestamp":1672853330000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1090634\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":42,"alternative-id":["10.3389\/fonc.2022.1090634"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.1090634","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"article-number":"1090634"}}